

## Taiwan Technology: Marketing feedback: Geopolitical risk, AI demand concerns top of mind; MediaTek's auto story underappreciated

### Taiwan Technology

Growth potential from PC market recovery and AI server ramp-up

Explore >



#### Bruce Lu

+886(2)2730-4185 | [bruce.lu@gs.com](mailto:bruce.lu@gs.com)  
Goldman Sachs (Asia) L.L.C., Taipei  
Branch

#### Evelyn Yu

+886(2)2730-4187 | [evelyn.yu@gs.com](mailto:evelyn.yu@gs.com)  
Goldman Sachs (Asia) L.L.C., Taipei  
Branch

On March 13-14th, we met with 40+ investors in Hong Kong. In general, we feel that the overall investor sentiment on the sector remains negative, with concerns around potential downside from AI demand, geopolitical risks, tariff impact, and much discussion around the possibility of TSMC/Intel collaboration. We note that investors are shifting focus away from AI-related plays in the near term, favoring a top-down view based on potential trade shifts from tariffs. Among our Taiwan semiconductor coverage, investor interests mainly focused on TSMC and MediaTek. We summarize our key takeaways below.

### **TSMC: discussion about Intel is top of mind, potential AI order cut as key concern**

**The relationship of TSMC/Intel is top concern among investors:** During our marketing trip in Hong Kong, the most asked questions from investors was around the relationship of TSMC/Intel, with discussion around our view of any competition change from Intel especially post the new Intel CEO [announcement](#); the possibility of the collaboration between TSMC/Intel as well as US government, etc. We reiterate our view as stated in our report: [\*TSMC \(2330.TW\): Consideration of media reports of potential strategic developments involving Intel and US tariff proposals \(14 Feb 2025\)\*](#), we think the strategic merit for a potential JV seems unclear as TSMC and Intel operate under different business models and different tool sets which would likely require extra investment. Additionally, TSMC's business strategy has been to remain independent and avoid entering into JVs that could compromise its neutral status with other clients. Also, TSMC has historically been very cautious about sharing its intellectual property (IP) with other companies. Therefore, a technology transfer agreement between TSMC and Intel would also seem uncharacteristic of TSMC's strategy.

To note, in the announcement of TSMC's US\$100bn capex investment (see our [report](#)), TSMC does not mention any potential JVs. The company's emphasis on expanding advanced semiconductor manufacturing and research in the U.S. suggests a commitment to maintaining its independence and avoiding entering into

---

Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to [www.gs.com/research/hedge.html](http://www.gs.com/research/hedge.html). Analysts employed by non-US affiliates are not registered/qualified as research analysts with FINRA in the U.S.

JVs that could compromise its neutral status with other clients, in our view.

**Long term profitability guidance unchanged despite the US\$100bn investment:** We highlighted again to investors that, despite the further investment in the U.S., TSMC has not changed its long-term GM guidance, which remains at '53% and higher' range. Moreover, the GM dilution guidance - 2-3ppts in the next 5 years from overseas expansion - also remains unchanged. However, we believe the new investment - the accelerated/expanded scope of investment in the US with higher costs - largely explains why management did not raise long-term profitability target during its last analyst meeting, despite higher pricing this year.

**Potential further order cuts from AI demand:** Most investors have concerns over the sustainability of AI demand and whether we will see another round of AI order cuts in the near term. While we do not rule out the possibility, we believe the potential downside would most likely be due to geopolitical risks, including 1) US government's potential new export control frameworks for advanced AI chips, including towards Chinese AI customers, and 2) concerns over potential delays for the rollout of Nvidia GB200 NVL72 AI server racks due to supply constraints especially from downstream ODMs due to tariffs. To note, in our [report](#) published on 16 January, we cut our CoWoS shipment forecast by 6%/2% to 599k/975k wafers in 2025/26E (from 635k/999k wafers) to reflect our concerns.

### **MediaTek: earnings upside from underappreciated automotive**

**Automotive story largely underappreciated by investors:** MediaTek was one of the most frequently asked-about names by investors, following TSMC. We highlighted our new automotive business investment thesis for the name. In general, we feel that investors are not fully aware of the story and the potential earnings/revenue upside from the new automotive business.

As stated in our report: *MediaTek (2454.TW): Automotive as new driving force into 2026/2027; TP raised to NT\$1,780 (from NT\$1,700); reiterate Buy (10 March 2025)*, we are seeing further earnings upside coming from automotive TAM (total addressable market) expansion. We believe MediaTek has been securing design wins from major mainland China customers, thanks to its better cost performance, superior R&D support and customer services; we are expecting to see a more significant revenue ramp starting 2026. Looking ahead, we expect the ramp from mainland China's auto market should position the company well to further expand into non-mainland China OEM customers, with stronger demand for advanced cockpit solutions in 2027 and beyond. By 2026E/2027E, we are now expecting MediaTek's automotive business to contribute 3.6%/6.8% of its total revenue, up from 1.8% in 2025E. This will be largely driven by 1) market share gain within automotive cockpit SoC (system on chip) solutions over key global peers, and 2) product segment upgrade into mid to high end and high end segments with higher ASPs.

**The US CSP ASIC project remains key monitoring point:** The US CSP ASIC (application specific IC) project remains one of the key focus points for investors given the further expansion into the significant US\$45bn TAM in the AI ASIC market. We are

still expecting to see the project to tape-out in 2Q25. We believe once we see the successful project tape-out, it should become a strong share price catalyst. To us, this should represent a key milestone for MediaTek in showcasing their strong capability to enter into the Training AI segment, and potentially win over more projects beyond the current US CSP project.

**Other focus areas including ASE and second tier foundry**

OSAT (outsourced semiconductor assembly and test) industry was another focus point from investors, with ASE being the most asked-about name by investors. Within the OSAT industry, we prefer ASE over KYEC as we remain positive toward ASE's advanced packaging business, especially CoWoS (chip on wafer on substrate), which should continue to benefit from the overflow business from TSMC. We are positive over ASE's competitiveness on AI chip testing, and expect to see potential market share gain over KYEC in 2026. While some investors are worried about the downside from potential AI order cuts, we see limited impact on ASE for 2025 as of now, as the WoS side expansion from TSMC's overflow business should still mostly benefit ASE, with the current order cuts mostly in NSD (non-supporting demand), so the total shipment change from TSMC is likely limited.

We maintain our conservative view towards the mature foundry industry given the unfavorable supply demand outlook, with the ongoing aggressiveness on capacity build from mainland China. We believe pricing pressure will continue in the coming years.

## Investment Thesis, Price Target Risks and Methodology

TSMC is a leading global foundry company specializing in cutting-edge nodes. Its leading technology stance enables it to enjoy more than 60% of revenue share in the global foundry market. We like TSMC as we believe its solid technology leadership and execution better positions it vs. peers to capture the industry's long-term structural growth opportunities, particularly in areas such as AI/5G/HPC/EV. In addition, valuation looks attractive in our view, with the shares trading at the mid-end of their 10-year trading history (P/E: 10-29x). Furthermore, we view TSMC as the key AI enabler among our Taiwan Semis coverage, thanks to its leadership stance in leading edge nodes and advanced packaging technology - CoWoS (chip on wafer on substrate). We believe TSMC will achieve its 20% revenue CAGR target for the next several years, driven primarily by increasing silicon content growth and AI/HPC demand, with LT GM to remain at 53%+. We are Buy-rated on the stock.

### Price Target Risks and Methodology - TSMC (2330.TW/TSM)

**Valuation methodology:** We are Buy rated on the stock. We have a 12m TP of NT\$1,400, which is derived by applying a target P/E multiple of 20x to our 2026E EPS. Our 20x target P/E is benchmarked to its trading average during its last earnings upcycle where its 4-year earnings CAGR in 2018-2021 was 19.3% vs. our 3-year EPS CAGR at 24.4% during 2024-26E. For the ADR (TSM), we have a 12m TP of US\$259, based on a USD/TWD rate of 32.4 and ADR premium of 20% to reflect the stronger performance of SOX over Taiex especially starting 2024.

**Key downside risks to our views:** (1) further deterioration in end-demand recovery impacting capacity utilization; (2) slower customer node migrations; (3) further delays in 5G penetration resulting in slower long-term semiconductor content growth; (4) poor yields/execution resulting in worse-than-expected profitability; (5) stronger competition resulting in ASP/profitability erosion; and (6) unfavorable FX trend or higher-than-expected cost increase weighing on the margin outlook.

### Investment Thesis - MediaTek (2454.TW)

MediaTek is a leading global IC design house specializing in smartphone AP (application processor). We are positive on MediaTek, with the global smartphone market and its revenue to resume growth momentum from 2025E onwards. We think MediaTek is in a good position to transition to an AI play from a traditional smartphone AP provider, starting from AI smartphones, to enterprise ASICs and smart auto (partnering with Nvidia) solutions, etc., in 2025E-26E. We expect MediaTek to deliver decent multi-year growth, with revenue/earnings to grow by 16%/17% CAGR from 24-27E driven largely by 1) market share gains, especially in the premium segment (in particular, high-end 5G flagship SoCs), 2) smartphone upgrade cycle driven by GenAI demand, 3) new TAM (total addressable market) into enterprise ASIC and auto/computing markets. We are

Buy-rated on the stock.

### **Price Target Risks and Methodology - MediaTek (2454.TW)**

**Valuation:** We have a 12m TP of NT\$1,780. Our TP is based on a target P/E multiple of 20x (1stdv above its 5-year trading average) applied to our FY26E EPS.

**Key downside risks to our views:** (1) weaker-than-expected end demand, (2) slower TAM expansion for high-end 5G smartphones, (3) higher-than-expected foundry costs, (4) intensifying competition landscape, and (5) slower growth of its non-smartphone business.

### **Investment Thesis - ASE (3711.TW, ASX)**

ASE is the leading provider of semiconductor manufacturing services in assembly and test. We like ASE's leadership position within the OSAT sector and believe it will outperform peers via continued market share gains despite a volatile market dynamic. Furthermore, we now see a more attractive risk reward given 1) gradual demand recovery as inventory correction cycle comes to an end, 2) structural profitability improvement, and 3) new AI business opportunity as an incremental positive.

While its share is now trading at the high end of its 10-year trading history (P/E: 5-18x), we believe a valuation premium over through cycle average for ASE is justified given our positive outlook towards its margin-accretive new AI business. We thus see risk-reward skewed to the upside and have a Buy rating on ASE.

### **Price Target Risks and Methodology - ASE (3711.TW)**

**Valuation:** We are Buy rated on ASE with a 12m TP of NT\$205, which is derived by applying a target P/E multiple of 18x to our 2H25-1H26 EPS. For its ADR, our 12-month TP is US\$13.90 (based on FX conversion of 32.5 and a 10% ADR premium).

**Key downside risks to our views:** (1) weaker-than-expected end demand; (2) stronger competition and pricing pressure; (3) poor execution/yields; (4) slower-than-expected progress in advance packaging; and (5) worse geopolitical/FX movements.

# Disclosure Appendix

## Reg AC

We, Bruce Lu and Evelyn Yu, hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Goldman Sachs' Global Investment Research division.

## GS Factor Profile

The Goldman Sachs Factor Profile provides investment context for a stock by comparing key attributes to the market (i.e. our universe of rated stocks) and its sector peers. The four key attributes depicted are: Growth, Financial Returns, Multiple (e.g. valuation) and Integrated (a composite of Growth, Financial Returns and Multiple). Growth, Financial Returns and Multiple are calculated by using normalized ranks for specific metrics for each stock. The normalized ranks for the metrics are then averaged and converted into percentiles for the relevant attribute. The precise calculation of each metric may vary depending on the fiscal year, industry and region, but the standard approach is as follows:

**Growth** is based on a stock's forward-looking sales growth, EBITDA growth and EPS growth (for financial stocks, only EPS and sales growth), with a higher percentile indicating a higher growth company. **Financial Returns** is based on a stock's forward-looking ROE, ROCE and CROCI (for financial stocks, only ROE), with a higher percentile indicating a company with higher financial returns. **Multiple** is based on a stock's forward-looking P/E, P/B, price/dividend (P/D), EV/EBITDA, EV/FCF and EV/Debt Adjusted Cash Flow (DACF) (for financial stocks, only P/E, P/B and P/D), with a higher percentile indicating a stock trading at a higher multiple. The **Integrated** percentile is calculated as the average of the Growth percentile, Financial Returns percentile and (100% - Multiple percentile).

Financial Returns and Multiple use the Goldman Sachs analyst forecasts at the fiscal year-end at least three quarters in the future. Growth uses inputs for the fiscal year at least seven quarters in the future compared with the year at least three quarters in the future (on a per-share basis for all metrics).

For a more detailed description of how we calculate the GS Factor Profile, please contact your GS representative.

## M&A Rank

Across our global coverage, we examine stocks using an M&A framework, considering both qualitative factors and quantitative factors (which may vary across sectors and regions) to incorporate the potential that certain companies could be acquired. We then assign a M&A rank as a means of scoring companies under our rated coverage from 1 to 3, with 1 representing high (30%-50%) probability of the company becoming an acquisition target, 2 representing medium (15%-30%) probability and 3 representing low (0%-15%) probability. For companies ranked 1 or 2, in line with our standard departmental guidelines we incorporate an M&A component into our target price. M&A rank of 3 is considered immaterial and therefore does not factor into our price target, and may or may not be discussed in research.

## Quantum

Quantum is Goldman Sachs' proprietary database providing access to detailed financial statement histories, forecasts and ratios. It can be used for in-depth analysis of a single company, or to make comparisons between companies in different sectors and markets.

## Disclosures

### Rating and pricing information

ASE Technology Holding (Buy, NT\$155.00), ASE Technology Holding (ADR) (Buy, \$9.66), MediaTek (Buy, NT\$1,400.00), TSMC (Buy, NT\$959.00) and TSMC (ADR) (Buy, \$174.09)

**The rating(s) for ASE Technology Holding, ASE Technology Holding (ADR), MediaTek, TSMC and TSMC (ADR) is/are relative to the other companies in its/their coverage universe:** ASE Technology Holding, ASE Technology Holding (ADR), Aspeed, GlobalWafers Co., King Yuan Electronics Co., MediaTek, Novatek Microelectronics, Parade Technologies Ltd., Realtek Semiconductor Corp., Silergy Corp., TSMC, TSMC (ADR), United Microelectronics Corp., United Microelectronics Corp. (ADR), Vanguard International Corp., uPI

### Company-specific regulatory disclosures

The following disclosures relate to relationships between The Goldman Sachs Group, Inc. (with its affiliates, "Goldman Sachs") and companies covered by Goldman Sachs Global Investment Research and referred to in this research.

Goldman Sachs has received compensation for investment banking services in the past 12 months: TSMC (NT\$959.00) and TSMC (ADR) (\$174.09)

Goldman Sachs expects to receive or intends to seek compensation for investment banking services in the next 3 months: ASE Technology Holding (NT\$155.00), ASE Technology Holding (ADR) (\$9.66), MediaTek (NT\$1,400.00), TSMC (NT\$959.00) and TSMC (ADR) (\$174.09)

Goldman Sachs has received compensation for non-investment banking services during the past 12 months: TSMC (NT\$959.00) and TSMC (ADR) (\$174.09)

Goldman Sachs had an investment banking services client relationship during the past 12 months with: ASE Technology Holding (NT\$155.00), ASE Technology Holding (ADR) (\$9.66), MediaTek (NT\$1,400.00), TSMC (NT\$959.00) and TSMC (ADR) (\$174.09)

Goldman Sachs had a non-investment banking securities-related services client relationship during the past 12 months with: TSMC (NT\$959.00) and TSMC (ADR) (\$174.09)

Goldman Sachs had a non-securities services client relationship during the past 12 months with: MediaTek (NT\$1,400.00), TSMC (NT\$959.00) and TSMC (ADR) (\$174.09)

Goldman Sachs makes a market in the securities or derivatives thereof: ASE Technology Holding (NT\$155.00), ASE Technology Holding (ADR) (\$9.66), TSMC (NT\$959.00) and TSMC (ADR) (\$174.09)

Goldman Sachs is a specialist in the relevant securities and will at any given time have an inventory position, "long" or "short," and may be on the opposite side of orders executed on the relevant exchange: TSMC (NT\$959.00) and TSMC (ADR) (\$174.09)

Goldman Sachs Investment Research global Equity coverage universe

As of January 1, 2025, Goldman Sachs Global Investment Research had investment ratings on 3,021 equity securities. Goldman Sachs assigns stocks as Buys and Sells on various regional Investment Lists; stocks not so assigned are deemed Neutral. Such assignments equate to Buy, Hold and Sell for the purposes of the above disclosure required by the FINRA Rules. See 'Ratings, Coverage universe and related definitions' below. The Investment Banking Relationships chart reflects the percentage of subject companies within each rating category for whom Goldman Sachs has provided investment banking services within the previous twelve months.

**TSMC (2330.TW)** Stock Price Currency: Taiwan Dollar

**Goldman Sachs rating and stock price target history**


Source: Goldman Sachs Investment Research for ratings and price targets; FactSet closing prices as of 12/31/2024.

Legend:


- Rating (Blue square)
- Price target (Blue star)
- Price target at removal (Blue cross)
- Taiwan SE Weighted Index (Grey line)
- Covered by Bruce Lu (Light blue line)
- Not covered by current analyst (Dashed blue line)

Month	Rating	Price target	Price target at removal	Covered by Bruce Lu	Not covered by current analyst
Feb 2022		1050			
Mar 2022		835			
Apr 2022		842			
May 2022		860			
Jun 2022		855			
Jul 2022		860			
Aug 2022		857			
Sep 2022		755			
Oct 2022		780			
Nov 2022		550			
Dec 2022		600			
Jan 2023		577			
Feb 2023		708			
Mar 2023		675			
Apr 2023		615			
May 2023		700			
Jun 2023		630			
Jul 2023		685			
Aug 2023		668			
Sep 2023		725			
Oct 2023		760			
Nov 2023		975			
Dec 2023		1160			
Jan 2024		1270			
Feb 2024		1320			
Mar 2024					
Apr 2024					
May 2024					
Jun 2024					
Jul 2024					
Aug 2024					
Sep 2024					
Oct 2024					
Nov 2024					
Dec 2024					


The price targets shown should be considered in the context of all prior published Goldman Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.



The price targets shown should be considered in the context of all prior published Goldman Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.




The price targets shown should be considered in the context of all prior published Goldman Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.



The price targets shown should be considered in the context of all prior published Goldman Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.





The price targets shown should be considered in the context of all prior published Goldman Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.

## Regulatory disclosures

### Disclosures required by United States laws and regulations

See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; for equity securities, market making and/or specialist role. Goldman Sachs trades or may trade as a principal in debt securities (or in related derivatives) of issuers discussed in this report.

The following are additional required disclosures: **Ownership and material conflicts of interest:** Goldman Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage.

**Analyst compensation:** Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. **Analyst as officer or director:** Goldman Sachs policy generally prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director or advisor of any company in the analyst's area of coverage. **Non-U.S. Analysts:** Non-U.S. analysts may not be associated persons of Goldman Sachs & Co. LLC and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with subject company, public appearances and trading securities held by the analysts.

**Distribution of ratings:** See the distribution of ratings disclosure above. **Price chart:** See the price chart, with changes of ratings and price targets in prior periods, above, or, if electronic format or if with respect to multiple companies which are the subject of this report, on the Goldman Sachs website at <https://www.gs.com/research/hedge.html>.

### Additional disclosures required under the laws and regulations of jurisdictions other than the United States

The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. **Australia:** Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit-taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of Global Investment Research of Goldman Sachs Australia may attend site visits and other meetings hosted by the companies and other entities which are the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. To the extent that the contents of this document contains any financial product advice, it is general advice only and has been prepared by Goldman Sachs without taking into account a client's objectives, financial situation or needs. A client should, before acting on any such advice, consider the appropriateness of the advice having regard to the client's own objectives, financial situation and needs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests and a copy of Goldman Sachs' Australian Sell-Side Research Independence Policy Statement are available at: <https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html>. **Brazil:** Disclosure information in relation to CVM Resolution n. 20 is available at <https://www.gs.com/worldwide/brazil/area/gir/index.html>. Where applicable, the Brazil-registered analyst primarily responsible for the content of this research report, as defined in Article 20 of CVM Resolution n. 20, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. **Canada:** This information is being provided to you for information purposes only and is not, and under no circumstances should be construed as, an advertisement, offering or solicitation by Goldman Sachs & Co. LLC for purchasers of securities in Canada to trade in any Canadian security. Goldman Sachs & Co. LLC is not registered as a dealer in any jurisdiction in Canada under applicable Canadian securities laws and generally is not permitted to trade in Canadian securities and may be prohibited from selling certain securities and products in certain jurisdictions in Canada. If you wish to trade in any Canadian securities or other products in Canada please contact Goldman Sachs Canada Inc., an affiliate of The Goldman Sachs Group Inc., or another registered Canadian dealer. **Hong Kong:** Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. **India:** Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research Analyst - SEBI Registration Number INH000001493, 951-A, Rational House, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India, Corporate Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies referred to in this research report. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Goldman Sachs (India) Securities Private Limited compliance officer and investor grievance contact details can be found at this link: <https://publishing.gs.com/disclosures/hedge.html> - /general/equity. **Japan:** See below. **Korea:** This research, and any access to it, is intended only for "professional investors" within the meaning of the Financial Services and Capital Markets Act, unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. **New Zealand:** Goldman Sachs New Zealand Limited and its affiliates are neither "registered banks" nor "deposit takers" (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for "wholesale clients" (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests is available at: <https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html>. **Russia:** Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not



provide appraisal within the meaning of the Russian legislation on appraisal activity. Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. **Singapore:** Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this research, and should be contacted with respect to any matters arising from, or in connection with, this research. **Taiwan:** This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. **United Kingdom:** Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.

**European Union and United Kingdom:** Disclosure information in relation to Article 6 (2) of the European Commission Delegated Regulation (EU) (2016/958) supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council (including as that Delegated Regulation is implemented into United Kingdom domestic law and regulation following the United Kingdom's departure from the European Union and the European Economic Area) with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest is available at <https://www.gs.com/disclosures/europeanpolicy.html> which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

**Japan:** Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan Type II Financial Instruments Firms Association, The Investment Trusts Association, Japan, and Japan Investment Advisers Association. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

## Ratings, coverage universe and related definitions

**Buy (B), Neutral (N), Sell (S)** Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a Buy or Sell on an Investment List is determined by a stock's total return potential relative to its coverage universe. Any stock not assigned as a Buy or a Sell on an Investment List with an active rating (i.e., a stock that is not Rating Suspended, Not Rated, Early-Stage Biotech, Coverage Suspended or Not Covered), is deemed Neutral. Each region manages Regional Conviction Lists, which are selected from Buy rated stocks on the respective region's Investment Lists and represent investment recommendations focused on the size of the total return potential and/or the likelihood of the realization of the return across their respective areas of coverage. The addition or removal of stocks from such Conviction Lists are managed by the Investment Review Committee or other designated committee in each respective region and do not represent a change in the analysts' investment rating for such stocks.

**Total return potential** represents the upside or downside differential between the current share price and the price target, including all paid or anticipated dividends, expected during the time horizon associated with the price target. Price targets are required for all covered stocks. The total return potential, price target and associated time horizon are stated in each report adding or reiterating an Investment List membership.

**Coverage Universe:** A list of all stocks in each coverage universe is available by primary analyst, stock and coverage universe at <https://www.gs.com/research/hedge.html>.

**Not Rated (NR).** The investment rating, target price and earnings estimates (where relevant) are removed pursuant to Goldman Sachs policy when Goldman Sachs is acting in an advisory capacity in a merger or in a strategic transaction involving this company, when there are legal, regulatory or policy constraints due to Goldman Sachs' involvement in a transaction, and in certain other circumstances. **Early-Stage Biotech (ES).** An investment rating and a target price are not assigned pursuant to Goldman Sachs policy when this company neither has a drug, treatment or medical device that has passed a Phase II clinical trial nor a license to distribute a post-Phase II drug, treatment or medical device. **Rating Suspended (RS).** Goldman Sachs Research has suspended the investment rating and price target for this stock, because there is not a sufficient fundamental basis for determining an investment rating or target price. The previous investment rating and target price, if any, are no longer in effect for this stock and should not be relied upon. **Coverage Suspended (CS).** Goldman Sachs has suspended coverage of this company. **Not Covered (NC).** Goldman Sachs does not cover this company.

## Global product; distributing entities

Goldman Sachs Global Investment Research produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based in Goldman Sachs offices around the world produce research on industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Corretora de Títulos e Valores Mobiliários S.A.; Public Communication Channel Goldman Sachs Brazil: 0800 727 5764 and / or [contatogoldmanbrasil@gs.com](mailto:contatogoldmanbrasil@gs.com). Available Weekdays (except holidays), from 9am to 6pm. Canal de Comunicação com o Público Goldman Sachs Brasil: 0800 727 5764 e/ou [contatogoldmanbrasil@gs.com](mailto:contatogoldmanbrasil@gs.com). Horário de funcionamento: segunda-feira à sexta-feira (exceto feriados), das 9h às 18h; in Canada by Goldman Sachs & Co. LLC; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman Sachs & Co. LLC. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom.

Goldman Sachs International ("GSI"), authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA, has approved this research in connection with its distribution in the United Kingdom.

**European Economic Area:** GSI, authorised by the PRA and regulated by the FCA and the PRA, disseminates research in the following jurisdictions within the European Economic Area: the Grand Duchy of Luxembourg, Italy, the Kingdom of Belgium, the Kingdom of Denmark, the Kingdom of Norway, the Republic of Finland and the Republic of Ireland; GSI - Succursale de Paris (Paris branch) which is authorised by the French Autorité de contrôle prudentiel et de résolution ("ACPR") and regulated by the Autorité de contrôle prudentiel et de résolution and the Autorité des marchés financiers ("AMF") disseminates research in France; GSI - Sucursal en España (Madrid branch) authorized in Spain by the Comisión Nacional del Mercado de Valores disseminates research in the Kingdom of Spain; GSI - Sweden Bankfilial (Stockholm branch) is authorized by the SFSA as a "third country branch" in accordance with Chapter 4, Section 4 of the Swedish Securities and Market Act (Sv. lag (2007:528) om värdepappersmarknaden) disseminates research in the Kingdom of Sweden; Goldman Sachs Bank Europe SE ("GSBE") is a credit institution incorporated in Germany and, within the Single Supervisory Mechanism, subject to direct prudential supervision by the European Central Bank and in other respects supervised by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and Deutsche Bundesbank and disseminates research in the Federal Republic of Germany and those jurisdictions within the European Economic Area where GSI is not authorised to disseminate research and additionally, GSBE, Copenhagen Branch filial af GSBE, Tyskland, supervised by the Danish Financial Authority disseminates research in the Kingdom

of Denmark; GSBE - Sucursal en España (Madrid branch) subject (to a limited extent) to local supervision by the Bank of Spain disseminates research in the Kingdom of Spain; GSBE - Succursale Italia (Milan branch) to the relevant applicable extent, subject to local supervision by the Bank of Italy (Banca d'Italia) and the Italian Companies and Exchange Commission (Commissione Nazionale per le Società e la Borsa "Consob"); GSBE - Succursale de Paris (Paris branch), supervised by the AMF and by the ACPR disseminates research in France; and GSBE - Sweden Bankfilial (Stockholm branch), to a limited extent, subject to local supervision by the Swedish Financial Supervisory Authority (Finansinspektionen) disseminates research in the Kingdom of Sweden.

## General disclosures

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The information, opinions, estimates and forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by Global Investment Research. Goldman Sachs & Co. LLC, the United States broker dealer, is a member of SIPC (<https://www.sipc.org>).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

The analysts named in this report may have from time to time discussed with our clients, including Goldman Sachs salespersons and traders, or may discuss in this report, trading strategies that reference catalysts or events that may have a near-term impact on the market price of the equity securities discussed in this report, which impact may be directionally counter to the analyst's published price target expectations for such stocks. Any such trading strategies are distinct from and do not affect the analyst's fundamental equity rating for such stocks, which rating reflects a stock's return potential relative to its coverage universe as described herein.

We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research, unless otherwise prohibited by regulation or Goldman Sachs policy.

The views attributed to third party presenters at Goldman Sachs arranged conferences, including individuals from other parts of Goldman Sachs, do not necessarily reflect those of Global Investment Research and are not an official view of Goldman Sachs.

Any third party referenced herein, including any salespeople, traders and other professionals or members of their household, may have positions in the products mentioned that are inconsistent with the views expressed by analysts named in this report.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options and futures disclosure documents which are available from Goldman Sachs sales representatives or at <https://www.theocc.com/about/publications/character-risks.jsp> and [https://www.fiadocumentation.org/fia/regulatory-disclosures\\_1/fia-uniform-futures-and-options-on-futures-risk-disclosures-booklet-pdf-version-2018](https://www.fiadocumentation.org/fia/regulatory-disclosures_1/fia-uniform-futures-and-options-on-futures-risk-disclosures-booklet-pdf-version-2018). Transaction costs may be significant in option strategies calling for multiple purchase and sales of options such as spreads. Supporting documentation will be supplied upon request.

**Differing Levels of Service provided by Global Investment Research:** The level and types of services provided to you by Goldman Sachs Global Investment Research may vary as compared to that provided to internal and other external clients of GS, depending on various factors including your individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g., marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints. As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request that specific data underlying analysts' fundamental analysis available on our internal client websites be delivered to them electronically through data feeds or otherwise. No change to an analyst's fundamental research views (e.g., ratings, price targets, or material changes to earnings estimates for equity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to <https://research.gs.com>.

Disclosure information is also available at <https://www.gs.com/research/hedge.html> or from Research Compliance, 200 West Street, New York, NY 10282.

### © 2025 Goldman Sachs.

You are permitted to store, display, analyze, modify, reformat, and print the information made available to you via this service only for your own use. You may not resell or reverse engineer this information to calculate or develop any index for disclosure and/or marketing or create any other derivative works or commercial product(s), data or offering(s) without the express written consent of Goldman Sachs. You are not permitted to publish, transmit, or otherwise reproduce this information, in whole or in part, in any format to any third party without the express written consent of Goldman Sachs. This foregoing restriction includes, without limitation, using, extracting, downloading or retrieving this information, in whole or in part, to train or finetune a machine learning or artificial intelligence system, or to provide or reproduce this information, in whole or in part, as a prompt or input to any such system.